Five-Year Longitudinal Assessment (2008 to 2012) of E-101 Solution Activity against Clinical Target and Antimicrobial-Resistant Pathogens | Zendy

Gerald A. Denys | Zendy; Chris M. Pillar | Zendy; Daniel F. Sahm | Zendy; P O’Hanley | Zendy; Jackson T. Stephens | Zendy

Open Access

Five-Year Longitudinal Assessment (2008 to 2012) of E-101 Solution Activity against Clinical Target and Antimicrobial-Resistant Pathogens

Author(s) -

Gerald A. Denys,

Chris M. Pillar,

Daniel F. Sahm,

P O’Hanley,

Jackson T. Stephens

Publication year - 2014

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.03020-14

Subject(s) - antimicrobial , gram , microbiology and biotechnology , myeloperoxidase , biology , antibiotic resistance , bacteria , antibiotics , immunology , genetics , inflammation

This study summarizes the topical E-101 solution susceptibility testing results for 760 Gram-positive and Gram-negative target pathogens collected from 75 U.S. sites between 2008 and 2012 and 103 ESKAPE pathogens. E-101 solution maintained potent activity against all bacterial species studied for each year tested, with MICs ranging from <0.008 to 0.25 μg porcine myeloperoxidase (pMPO)/ml. These results confirm that E-101 solution retains its potent broad-spectrum activity against U.S. clinical isolates and organisms with challenging resistance phenotypes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research